Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8044580 | 0.78 | ALDH1A1 (0.45) | CYP2D6TSHRTDP1ALDH1A1CA12 | |
| SCHEMBL12448087 | 0.78 | CA12 (0.43) | CYP2D6TSHRTDP1ALDH1A1CA12 | |
| SCHEMBL31616908 | 0.77 | ALDH1A1 (0.46) | CYP2D6ALDH1A1KDM1A | |
| SCHEMBL21348399 | 0.77 | ALDH1A1 (0.44) | CYP2D6TSHRTDP1ALDH1A1CA12 | |
| SCHEMBL39800 | 0.75 | CA12 (0.47) | CYP2D6TSHRTDP1ALDH1A1CA12 | |
| SCHEMBL8041394 | 0.74 | TSHR (0.51) | CYP2D6TSHRTDP1ALDH1A1CA12 | |
| SCHEMBL4401738 | 0.74 | CA12 (0.53) | TDP1ALDH1A1CA12CA1CA2 | |
| SCHEMBL15025381 | 0.74 | CA12 (0.43) | CYP2D6TSHRTDP1ALDH1A1CA12 | |
| SCHEMBL21120467 | 0.73 | CYP2D6 (0.47) | CYP2D6TSHRTDP1NPSR1ALDH1A1 | |
| SCHEMBL12283058 | 0.73 | USP2 (0.48) | CYP2D6TSHRNPSR1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-01 | — | — | US | disclosed |
| WO-2018039641-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | PHARMATROPHIX, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-9464066-B2 | Deuterated compounds useful for treating neurodegenerative diseases | PHARMATROPHIX, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464066-B2 | Deuterated compounds useful for treating neurodegenerative diseases | PHARMATROPHIX, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | Ricerca Biosciences, LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | Ricerca Biosciences, LLC | 2016-08-11 | — | — | US | disclosed |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | PHARMATROPHIX, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | PHARMATROPHIX, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | NLN, NGF, BDNF | CYP2D6 3805/4885TSHR 1366/4885TDP1 666/4885 |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | NLN, NGF, BDNF | CYP2D6 3805/4885TSHR 1366/4885TDP1 666/4885 |
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | ADH1A, NTRK2, ADH1C | CYP2D6 3006/4885TSHR 623/4885TDP1 1711/4885 |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | BDNF, NTRK2, NGF | CYP2D6 4848/4885TSHR 439/4885TDP1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.